Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
09/13/2007 | US20070212769 Transfection, culturing; electrophoresis |
09/13/2007 | US20070212753 Altered antibodies and their preparation |
09/13/2007 | US20070212743 Assays for Determining Anticoagulant Cofactor Activity |
09/13/2007 | US20070212728 32263, a novel human biotin enzyme and uses thereof |
09/13/2007 | US20070212714 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof |
09/13/2007 | US20070212701 Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof |
09/13/2007 | US20070212686 Use Of T-Cadherin As A Target |
09/13/2007 | US20070212418 Microparticles comprising somatostatin analogues |
09/13/2007 | US20070212414 Ethanol-resistant sustained release formulations |
09/13/2007 | US20070212404 Liposome And Method Of Preparing The Same |
09/13/2007 | US20070212390 Protease-resistant forms of VEGF-D, method of making and method of use |
09/13/2007 | US20070212384 Altering Animal Waste Compositiion |
09/13/2007 | US20070212383 Juvenile Hormone Compositions and Methods for Making Same |
09/13/2007 | US20070212380 Conjugated Fatty Acid Based Emulsion and Methods for Preparing and Using Same |
09/13/2007 | US20070212378 Methods And Compositions For Mycoplasma Pneumoniae Exotoxins |
09/13/2007 | US20070212372 Methods for the treatment and prophylaxis of demeyelinating disease |
09/13/2007 | US20070212370 Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
09/13/2007 | US20070212368 Proteins |
09/13/2007 | US20070212365 recombinantly produced polypeptide; contacting a vascular cell with polypeptide for inhibiting angiogeneisis |
09/13/2007 | US20070212363 Immunoglobulins with Potent and Broad Antiviral Activity |
09/13/2007 | US20070212362 Use of il-17 antibody for the treatment of cartilage damaged by osteoarthritis |
09/13/2007 | US20070212358 Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
09/13/2007 | US20070212354 Administering a therapeutically effective amount of a vascular endothelial growth factor (VEGF) antagonist dimeric protein comprising two fusion polypeptides |
09/13/2007 | US20070212351 Novel therapeutic targets in cancer |
09/13/2007 | US20070212348 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation |
09/13/2007 | US20070212347 Compositions and methods for treating polycystic kidney disease gene |
09/13/2007 | US20070212345 Methods And Compositions For The Prevention And Treatment Of Gentiourinary Disorders Including Pre-Term Labor And Leiomyomas |
09/13/2007 | US20070212344 Pharmaceutical preparation with RNA as hemostasis cofactor |
09/13/2007 | US20070212343 Compositions for treatment of ear infections |
09/13/2007 | US20070212342 Protease compositions for the treatment of damaged tissue |
09/13/2007 | US20070212341 Method for Preparing Active Kinases Containing Ph Domains |
09/13/2007 | US20070212340 Use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
09/13/2007 | US20070212339 Use Of At Least One Effector Of Glutathione Metabolism Together With Alpha-Lipoic Acid For The Treatment Of Chronically Obstructive Lung Diseases |
09/13/2007 | US20070212334 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
09/13/2007 | US20070212329 Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System |
09/13/2007 | US20070212308 Methods and compositions for treating asthma in human and non human primates |
09/13/2007 | US20070212306 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides |
09/13/2007 | US20070212300 Delivery of compounds with rehydrated blood cells |
09/13/2007 | US20070212298 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
09/13/2007 | DE60124710T2 Analoge des glucagon ähnlichen peptid-1 Analogs of glucagon-like peptide-1 |
09/13/2007 | DE102006009437A1 G-CSF-Flüssigformulierung G-CSF liquid formulation |
09/13/2007 | CA2680228A1 Modified molecules which promote hematopoiesis |
09/13/2007 | CA2645550A1 Use of peptides for the control of radiation injury |
09/13/2007 | CA2645277A1 Compositions and methods based on peptide binding profiling |
09/13/2007 | CA2645142A1 Regulating stem cells |
09/13/2007 | CA2645019A1 Methods for regulating inflammatory mediators and peptides useful therein |
09/13/2007 | CA2644952A1 Methods and compositions related to cyclic peptide synthesis |
09/13/2007 | CA2644712A1 Unstructured recombinant polymers and uses thereof |
09/13/2007 | CA2644255A1 Chimeric kunitz domains and their use |
09/13/2007 | CA2644241A1 Treatment with cyclosporin a |
09/13/2007 | CA2644127A1 Human interferon-gamma (infgamma) variants |
09/13/2007 | CA2644020A1 Prolongation of survival of an allograft by inhibiting complement activity |
09/13/2007 | CA2643337A1 Cancer treatment combining lymphodepleting agent with ctls and cytokines |
09/12/2007 | EP1832663A2 Uses of DNA-PK |
09/12/2007 | EP1832653A1 MN gene and protein |
09/12/2007 | EP1832603A2 Stabilised mRNA with increased G/C-content and optimised codon usage for gene therapy |
09/12/2007 | EP1832599A2 Albumin fusion proteins |
09/12/2007 | EP1832297A1 Anticoagulant agents useful in treatment of thrombosis |
09/12/2007 | EP1832296A1 Composition for treating or preventing myocardial disorder or heart failure |
09/12/2007 | EP1832295A1 Use of PTX3 for the treatment of viral diseases |
09/12/2007 | EP1831373A2 Recombinant production of serum albumin |
09/12/2007 | EP1831371A2 Muteins of fibroblast growth factor 21 |
09/12/2007 | EP1831354A1 Platelet-derived growth factor-responsive neural precursor cells and progeny thereof |
09/12/2007 | EP1831254A2 Conjugation product |
09/12/2007 | EP1831253A1 Combination therapy for b cell disorders |
09/12/2007 | EP1831252A1 Glp-1 analog fusion protein formulations |
09/12/2007 | EP1831245A1 Antimicrobial peptides with reduced hemolysis and methods of their use |
09/12/2007 | EP1830924A1 Prevention of thrombus formation and/or stabilization |
09/12/2007 | EP1830874A2 Compositions for enhancing keratinocyte migration and epidermal repair via a receptor containing osmrbeta as a subunit, and applications thereof |
09/12/2007 | EP1830873A1 Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions |
09/12/2007 | EP1830872A2 Fusion proteins |
09/12/2007 | EP1830871A1 Compositions for hcv treatment |
09/12/2007 | EP1830870A1 Compounds for flaviviridae treatment |
09/12/2007 | EP1830869A1 Method of treatment or prophylaxis |
09/12/2007 | EP1830868A1 Dap-10 and uses thereof |
09/12/2007 | EP1830867A2 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv |
09/12/2007 | EP1830866A2 METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE |
09/12/2007 | EP1830863A2 Protein formulation |
09/12/2007 | EP1830845A2 Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level |
09/12/2007 | EP1830818A1 Process for the manufacture of sterile suspensions or lyophilisates of low-soluble basic peptide complexes, pharmaceutical formulations comprising these complexes and their use as medicament |
09/12/2007 | EP1718673B1 Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same |
09/12/2007 | EP1658093B1 Use of a mixture containing oxytocin and testosteron or estradiol for treating disturbances of psychosocial experiences and behaviour |
09/12/2007 | EP1581247A4 Methods and compositions for treating polycystic ovary syndrome |
09/12/2007 | EP1463836A4 Vector mediated organelle transfection |
09/12/2007 | EP1444201B1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors |
09/12/2007 | EP1443988B1 Device for controlled enzymatic removal and retrieval of tissue |
09/12/2007 | EP1407013B1 Mutations in ion channels |
09/12/2007 | EP1395255A4 Cddo-compounds and combination therapies thereof |
09/12/2007 | EP1389915B1 The use of food and drink as a delevery system for phytase in humans |
09/12/2007 | EP1372615A4 Compounds and compositions for delivering active agents |
09/12/2007 | EP1354945B1 Method of identifying within a rodent a dna encoding physiologically active polypeptide |
09/12/2007 | EP1307564B1 Compounds and methods for treatment and diagnosis of chlamydial infection |
09/12/2007 | EP1299541B1 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
09/12/2007 | EP1224266B1 Lysosomal targeting pathway enzymes |
09/12/2007 | EP1212366B1 Therapeutic compounds comprised of anti-fc receptor binding agents |
09/12/2007 | EP1154788B9 Method for indentifying compounds that modulate sister chromatid separation |
09/12/2007 | EP1133312B1 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
09/12/2007 | EP0993613B1 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |
09/12/2007 | EP0970127B1 Induction of immunological tolerance to a therapeutic antibody using variants of the said therapeutic antibody |
09/12/2007 | EP0964874B1 A lymphocyte surface receptor that binds caml, nucleic acids encoding the same and methods of use thereof |